Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma.

Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305-5655, USA.
Anticancer research (Impact Factor: 1.87). 26(3A):1739-43.
Source: PubMed

ABSTRACT Hepatocellular carcinoma (HCC) is a particularly lethal cancer with few treatment options. Since gallium is known to accumulate specifically in HCC tumors but not in non-tumor liver, we investigated two gallium compounds, gallium nitrate (GaN) and gallium maltolate (GaM), as potential new agents for treating HCC.
The anti-proliferative and apoptotic activities of GaN and GaM were assessed in vitro using four HCC cell lines. HCC gene expression data was analyzed to provide a mechanistic rationale for using gallium in the treatment of HCC.
Both compounds showed dose-dependent antiproliferative activity in all four HCC cell lines after 6-day drug exposure (IC50 values range from 60-250 microM for gallium nitrate and 25-35 microM for gallium maltolate). Gallium maltolate at 30 microM additionally induced apoptosis after 6 days. HCC gene expression data showed significantly elevated expression of the M2 subunit of ribonucleotide reductase, which is a target for the antiproliferative activity of gallium.
These data support clinical testing of gallium maltolate, an orally active compound, in the treatment of HCC.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Due to the antitumor activity of Gallium MAL complex, as well as recent findings on new targeted biomolecules in malignant cells through this complex, the development of radiolabeled gallium complex for future imaging studies was targeted. Ga-67 labeled 3-hydroxy-2-methyl-4H-pyran-4-onate (Ga-67 MAL) was prepared using freshly prepared Ga-67 chloride and 3-hydroxy-2-methyl-4H-pyran-4-onate in a sodium salt form in 25 min at 40° C. The stability of the complex was checked in final formulation and human serum for 24 h followed by the administration in Swiss mice for biodistribution studies. The complex was prepared in high radiochemical purity (> 97% ITLC, > 98% HPLC) and specific activity of 13-14 GBq/mmol and was stable in the presence of serum for 48 h. The partition coefficient was calculated for the compound (log p = 0.40). A detailed comparative pharmacokinetic study was performed for Ga-67 cation and Ga-67-MAL. The complex is more rapidly washed out from the circulation through kidneys and liver compared to Ga-67 cation and can be an interesting tumor imaging agent due to the fact that the cold compound is undergoing clinical trials as a safe and potential therapeutic agent for cancer.
    Iranian journal of pharmaceutical research (IJPR) 01/2012; 11(3):755-62. · 0.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acetylated glucosamine conjugation shows enhancement of in vitro cytotoxicity for a bis-pyrazole ligated Zn(II) complex against HeLa WT and MCF-7. The presence of glucosamine leads to more accumulation of Zn(II) inside MCF-7 which promotes caspase 7 activation leading to apoptosis. Flow cytometry studies showed cell cycle arrest in G2/M phase.
    Journal of Inorganic Biochemistry 11/2014; 140:131–142. · 3.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanomedicines are enjoying a widespread popularity realizing their intriguing potential to solve drug delivery obstacles. Assessment of major quality attributes of nanocarriers is a crucial process for approving their therapeutic outcomes. Disparate assessment methods were employed that recently encompassed cell line technique. Routinely, cell line model was viewed as an excellent platform for gene and vaccine delivery. However, its application in pharmaceutical assessment of nanocarriers was not so far overviewed. This review provides a meticulous look at cell culture implementations in evaluation of major quality attributes of nanocarriers, including oral permeability, cytotoxicity and efficiency of tumor targeting. Among others, cell culture technique strikes the right balance between predictability and throughput. It could circumvent drawbacks of in-vivo and in-vitro techniques while gathering privileges of both. Imperative pharmaceutical considerations demanded for proper application of this technique were emphasized. Furthermore, challenges encountered in assessment of versatile nanocarriers were highlighted with proposed solutions. Finally, future research perspectives in this theme issue were suggested.
    Journal of Controlled Release 09/2014; · 7.26 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014